Alprazolam side effects: what 204,870 FDA adverse event reports show
Who reports
204,870 reports · 71% serious · 33,446 with death outcome · 68% female
Used for
Alprazolam extended-release tablets are indicated for the treatment of panic disorder with or without agoraphobia, in adults. Alprazolam extended-release tablets are a benzodiazepine indicated for the treatment of panic disorder with or without agoraphobia, in adults. ( 1 )
What it is
Alprazolam is a member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively.
Boxed warning
RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate.
Causality screen of the 40 strongest signals
What the badges mean
- Labeled — boxed warning The term (or its clinical synonym) appears in the FDA boxed warning: causality is regulator-recognised and considered serious.
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Outcome field, not a reaction Death is a report outcome, not a reaction term. It is dominated by the underlying illness; see the seriousness profile and the boxed warning instead.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 1,113 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Vaginal flatulence | 188 | 164.9 130.7–208.1ROR 165.0 · χ² 11,497 / p <1e-300 | 62.5 EB05 55.3 · IC025 +5.5 3/3 methods agree | Not in label — unassessed | serious n=188 · ♀ 100% (drug 68%) · 100% clinician | not reported in cached trials |
| Prescription form tampering | 184 | 32.0 27.1–37.8ROR 32.0 · χ² 4,162 / p <1e-300 | 24.4 EB05 21.6 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=184 · ♀ 0% (drug 68%) · 100% clinician | not reported in cached trials |
| Sopor | 2,105 | 19.0 18.1–19.9ROR 19.2 · χ² 30,142 / p <1e-300 | 16.1 EB05 15.5 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious PRR 13.1 · 95% clinician | not reported in cached trials |
| Poisoning deliberate | 1,439 | 18.6 17.6–19.7ROR 18.7 · χ² 20,178 / p <1e-300 | 15.8 EB05 15.1 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious PRR 12.9 · 100% clinician | not reported in cached trials |
| Drug abuse | 11,121 | 15.6 15.3–15.9ROR 16.4 · χ² 131,675 / p <1e-300 | 13.6 EB05 13.4 · IC025 +3.7 3/3 methods agree | Reporting / coding artifact | serious PRR 11.2 · ♀ 45% (drug 68%) · 91% clinician | not reported in cached trials |
| Poisoning | 1,659 | 15.4 14.6–16.2ROR 15.5 · χ² 19,314 / p <1e-300 | 13.4 EB05 12.9 · IC025 +3.7 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 11.0 · 100% clinician | not reported in cached trials |
| Female genital tract fistula | 213 | 14.3 12.4–16.5ROR 14.3 · χ² 2,299 / p <1e-300 | 12.6 EB05 11.2 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=213 · ♀ 100% (drug 68%) · 100% clinician | not reported in cached trials |
| Chronic kidney disease-mineral and bone disorder | 132 | 14.2 11.8–17.0ROR 14.2 · χ² 1,406 / p <1e-300 | 12.5 EB05 10.8 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=132 · ♀ 0% (drug 68%) | not reported in cached trials |
| Drug use disorder | 951 | 13.2 12.3–14.1ROR 13.2 · χ² 9,442 / p <1e-300 | 11.7 EB05 11.1 · IC025 +3.4 3/3 methods agree | Labeled (related wording) related wording | serious PRR 9.8 | not reported in cached trials |
| Radiculopathy | 289 | 12.5 11.1–14.1ROR 12.5 · χ² 2,705 / p <1e-300 | 11.2 EB05 10.1 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious n=283 · ♀ 100% (drug 68%) | not reported in cached trials |
| Exposure via ingestion | 267 | 11.9 10.4–13.5ROR 11.9 · χ² 2,363 / p <1e-300 | 10.6 EB05 9.6 · IC025 +3.2 3/3 methods agree | Reporting / coding artifact | serious n=255 · ♀ 47% (drug 68%) · 100% clinician | not reported in cached trials |
| Respiratory arrest | 2,808 | 11.4 11.0–11.8ROR 11.5 · χ² 23,924 / p <1e-300 | 10.3 EB05 10.0 · IC025 +3.3 3/3 methods agree | Not in label — unassessed | serious PRR 8.4 · 95% clinician | not reported in cached trials |
| Nephrogenic anaemia | 450 | 10.8 9.8–11.9ROR 10.8 · χ² 3,605 / p <1e-300 | 9.8 EB05 9.1 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=450 | not reported in cached trials |
| Substance abuse | 782 | 10.8 10.0–11.6ROR 10.8 · χ² 6,243 / p <1e-300 | 9.8 EB05 9.2 · IC025 +3.2 3/3 methods agree | Reporting / coding artifact | serious PRR 8.6 · ♀ 45% (drug 68%) | not reported in cached trials |
| Multiple drug overdose intentional | 312 | 10.7 9.5–12.1ROR 10.7 · χ² 2,477 / p <1e-300 | 9.7 EB05 8.8 · IC025 +3.1 3/3 methods agree | Labeled (related wording) related wording | serious n=312 · 100% clinician | not reported in cached trials |
| Hyperparathyroidism secondary | 242 | 10.7 9.4–12.2ROR 10.7 · χ² 1,918 / p <1e-300 | 9.7 EB05 8.7 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=242 | not reported in cached trials |
| Multiple drug overdose | 480 | 10.7 9.7–11.7ROR 10.7 · χ² 3,801 / p <1e-300 | 9.7 EB05 9.0 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=480 · 100% clinician | not reported in cached trials |
| Bradypnoea | 255 | 10.6 9.4–12.1ROR 10.7 · χ² 2,006 / p <1e-300 | 9.6 EB05 8.7 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=255 · 100% clinician | not reported in cached trials |
| Temperature regulation disorder | 206 | 10.6 9.1–12.2ROR 10.6 · χ² 1,603 / p <1e-300 | 9.5 EB05 8.5 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=197 · ♀ 100% (drug 68%) · 100% clinician | not reported in cached trials |
| Accidental death | 173 | 10.4 8.9–12.2ROR 10.5 · χ² 1,329 / p 2e-291 | 9.4 EB05 8.3 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=173 · ♀ 0% (drug 68%) · 100% clinician | not reported in cached trials |
| Substance use disorder | 283 | 10.3 9.1–11.6ROR 10.3 · χ² 2,141 / p <1e-300 | 9.3 EB05 8.5 · IC025 +3.0 3/3 methods agree | Labeled adverse reaction exact term | serious n=283 · ♀ 36% (drug 68%) · 100% clinician | not reported in cached trials |
| Chronic sinusitis | 344 | 10.3 9.2–11.5ROR 10.3 · χ² 2,598 / p <1e-300 | 9.3 EB05 8.5 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=330 · ♀ 100% (drug 68%) | not reported in cached trials |
| Completed suicide (death by suicide) | 7,649 | 10.1 9.9–10.4ROR 10.5 · χ² 57,465 / p <1e-300 | 9.3 EB05 9.1 · IC025 +3.2 3/3 methods agree | Outcome field, not a reaction boxed warning mentions mortality | serious PRR 7.6 · 96% clinician | not reported in cached trials |
| Homicide | 155 | 9.5 8.1–11.2ROR 9.5 · χ² 1,072 / p 2e-235 | 8.6 EB05 7.5 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=138 · ♀ 0% (drug 68%) · 100% consumer | not reported in cached trials |
| Drug diversion | 490 | 9.5 8.7–10.4ROR 9.5 · χ² 3,393 / p <1e-300 | 8.7 EB05 8.1 · IC025 +3.0 3/3 methods agree | Reporting / coding artifact | serious n=272 · ♀ 24% (drug 68%) · 100% consumer | not reported in cached trials |
| Macular degeneration | 981 | 9.1 8.5–9.7ROR 9.1 · χ² 6,478 / p <1e-300 | 8.4 EB05 8.0 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious PRR 7.4 · ♀ 100% (drug 68%) | not reported in cached trials |
| Rebound acid hypersecretion | 252 | 9.1 8.0–10.3ROR 9.1 · χ² 1,654 / p <1e-300 | 8.3 EB05 7.5 · IC025 +2.8 3/3 methods agree | Labeled (related wording) related wording | serious n=252 | not reported in cached trials |
| Alcohol abuse | 214 | 8.7 7.6–10.1ROR 8.8 · χ² 1,343 / p 2e-294 | 8.0 EB05 7.2 · IC025 +2.8 3/3 methods agree | Reporting / coding artifact | serious n=208 | not reported in cached trials |
| Proctitis | 219 | 8.6 7.5–9.9ROR 8.6 · χ² 1,346 / p 7e-295 | 7.9 EB05 7.0 · IC025 +2.8 3/3 methods agree | Not in label — unassessed | serious n=217 · ♀ 100% (drug 68%) · 100% clinician | not reported in cached trials |
| Suspected suicide | 325 | 7.4 6.6–8.3ROR 7.4 · χ² 1,674 / p <1e-300 | 6.9 EB05 6.3 · IC025 +2.6 3/3 methods agree | Labeled (related wording) related wording | serious n=325 · 100% clinician | not reported in cached trials |
| Bradyphrenia | 447 | 7.4 6.7–8.1ROR 7.4 · χ² 2,300 / p <1e-300 | 6.9 EB05 6.4 · IC025 +2.6 3/3 methods agree | Labeled adverse reaction exact term | serious n=428 | not reported in cached trials |
| Cardio-respiratory arrest | 2,850 | 7.4 7.1–7.6ROR 7.5 · χ² 14,627 / p <1e-300 | 6.9 EB05 6.7 · IC025 +2.7 3/3 methods agree | Not in label — unassessed | serious PRR 5.7 · 96% clinician | not reported in cached trials |
| Hallucinations, mixed | 284 | 7.3 6.5–8.3ROR 7.3 · χ² 1,442 / p <1e-300 | 6.8 EB05 6.2 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=277 | not reported in cached trials |
| Panic disorder | 256 | 7.2 6.3–8.1ROR 7.2 · χ² 1,263 / p 8e-277 | 6.7 EB05 6.0 · IC025 +2.5 3/3 methods agree | Likely indication confounding term in indications; also in warnings | serious n=216 | not reported in cached trials |
| Pre-existing condition improved | 409 | 7.0 6.4–7.8ROR 7.0 · χ² 1,970 / p <1e-300 | 6.6 EB05 6.1 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious n=182 | not reported in cached trials |
| Miosis | 512 | 7.0 6.4–7.6ROR 7.0 · χ² 2,440 / p <1e-300 | 6.5 EB05 6.1 · IC025 +2.6 3/3 methods agree | Not in label — unassessed | serious PRR 5.6 · ♀ 42% (drug 68%) · 100% clinician | not reported in cached trials |
| Suicide attempt | 3,736 | 6.6 6.4–6.9ROR 6.7 · χ² 16,836 / p <1e-300 | 6.3 EB05 6.1 · IC025 +2.6 3/3 methods agree | Labeled (related wording) related wording | serious PRR 5.1 | not reported in cached trials |
| Coma | 2,872 | 6.5 6.3–6.7ROR 6.6 · χ² 12,574 / p <1e-300 | 6.2 EB05 6.0 · IC025 +2.6 3/3 methods agree | Labeled — boxed warning exact term | serious PRR 5.0 | not reported in cached trials |
| Anxiety disorder | 199 | 6.4 5.5–7.4ROR 6.4 · χ² 844 / p 6e-186 | 6.0 EB05 5.3 · IC025 +2.3 3/3 methods agree | Labeled (related wording) related wording | serious n=177 | NCT03478982: 1/38 (2.6%) on Alprazolam |
| Drug abuser | 365 | 6.3 5.7–7.0ROR 6.3 · χ² 1,530 / p <1e-300 | 6.0 EB05 5.5 · IC025 +2.4 3/3 methods agree | Not in label — unassessed | serious n=365 · ♀ 39% (drug 68%) | not reported in cached trials |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Alprazolam as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (1 of 40 signal terms matched).
- NCT03478982 — Inpatient, Dose-Ranging Study of Staccato Alprazolam in Epilepsy With Predictable Seizure Pattern (N=156, PHASE2; 47 AE terms posted; arms: Open-label: Staccato Alprazolam (STAP-00; Double-blind: Placebo; Double-blind: Staccato Alprazolam 1.0 mg; Double-blind: Staccato Alprazolam 2.0 mg)
- NCT00803400 — Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment (N=150, PHASE4; 2 AE terms posted; arms: Alprazolam; Alprazolam + Aerobic Exercise)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug ineffective (drug did not work) | 13,641 | 1.1 1.0–1.1ROR 1.1 · χ² 50 / p 7e-13 | 1.1 EB05 1.0 · IC025 +0.1 | Reporting / coding artifact | serious PRR 1.2 | not reported in cached trials |
| Nausea | 13,094 | 1.7 1.7–1.7ROR 1.8 · χ² 3,946 / p <1e-300 | 1.7 EB05 1.7 · IC025 +0.7 | Labeled adverse reaction exact term | serious PRR 1.6 | NCT03478982: 2/38 (5.3%) on Alprazolam; 1/40 (2.5%) control |
| Fatigue (tiredness) | 12,186 | 1.6 1.6–1.6ROR 1.7 · χ² 2,916 / p <1e-300 | 1.6 EB05 1.6 · IC025 +0.7 | Labeled adverse reaction exact term | serious PRR 1.5 | NCT03478982: 2/40 (5.0%) control |
| Drug abuse | 11,121 | 15.6 15.3–15.9ROR 16.4 · χ² 131,675 / p <1e-300 | 13.6 EB05 13.4 · IC025 +3.7 3/3 methods agree | Reporting / coding artifact | serious PRR 11.2 · ♀ 45% (drug 68%) · 91% clinician | not reported in cached trials |
| Anxiety | 10,315 | 3.8 3.7–3.9ROR 4.0 · χ² 20,807 / p <1e-300 | 3.7 EB05 3.6 · IC025 +1.9 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 3.2 | NCT03478982: 1/38 (2.6%) on Alprazolam |
| Headache | 10,113 | 1.7 1.6–1.7ROR 1.7 · χ² 2,714 / p <1e-300 | 1.7 EB05 1.6 · IC025 +0.7 | Labeled adverse reaction exact term | serious PRR 1.7 | NCT03478982: 1/38 (2.6%) on Alprazolam; 2/40 (5.0%) control |
| Pain | 9,971 | 1.7 1.6–1.7ROR 1.7 · χ² 2,711 / p <1e-300 | 1.7 EB05 1.6 · IC025 +0.7 | Labeled adverse reaction exact term | serious PRR 1.6 | NCT03478982: 1/38 (2.6%) on Alprazolam |
| Toxicity to various agents | 9,057 | 5.8 5.7–5.9ROR 6.0 · χ² 34,145 / p <1e-300 | 5.5 EB05 5.4 · IC025 +2.4 3/3 methods agree | Not in label — unassessed | serious PRR 4.6 | not reported in cached trials |
| Diarrhoea (diarrhea) | 9,012 | 1.4 1.4–1.5ROR 1.5 · χ² 1,232 / p 4e-270 | 1.4 EB05 1.4 · IC025 +0.5 | Labeled adverse reaction exact term | serious PRR 1.3 | not reported in cached trials |
| Dyspnoea (shortness of breath) | 8,437 | 1.5 1.5–1.6ROR 1.6 · χ² 1,590 / p <1e-300 | 1.5 EB05 1.5 · IC025 +0.6 | Labeled adverse reaction exact term | serious PRR 1.3 | not reported in cached trials |
| Dizziness | 8,013 | 1.7 1.6–1.7ROR 1.7 · χ² 2,107 / p <1e-300 | 1.6 EB05 1.6 · IC025 +0.7 | Labeled adverse reaction exact term | serious PRR 1.5 | NCT03478982: 2/38 (5.3%) on Alprazolam; 2/40 (5.0%) control |
| Completed suicide (death by suicide) | 7,649 | 10.1 9.9–10.4ROR 10.5 · χ² 57,465 / p <1e-300 | 9.3 EB05 9.1 · IC025 +3.2 3/3 methods agree | Outcome field, not a reaction boxed warning mentions mortality | serious PRR 7.6 · 96% clinician | not reported in cached trials |
| Depression | 7,324 | 3.4 3.3–3.4ROR 3.4 · χ² 11,848 / p <1e-300 | 3.3 EB05 3.2 · IC025 +1.7 3/3 methods agree | Labeled — boxed warning exact term | serious PRR 3.0 | not reported in cached trials |
| Vomiting | 7,293 | 1.6 1.6–1.6ROR 1.6 · χ² 1,657 / p <1e-300 | 1.6 EB05 1.6 · IC025 +0.6 | Labeled adverse reaction exact term | serious PRR 1.5 | NCT03478982: 1/38 (2.6%) on Alprazolam; 1/40 (2.5%) control |
| Insomnia (trouble sleeping) | 7,291 | 2.8 2.8–2.9ROR 2.9 · χ² 8,609 / p <1e-300 | 2.8 EB05 2.7 · IC025 +1.4 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 2.7 | not reported in cached trials |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Vaginal flatulence — n=188, PRR 164.9
- Prescription form tampering — n=184, PRR 32.0
- Sopor — n=2,105, PRR 19.0
- Poisoning deliberate — n=1,439, PRR 18.6
- Female genital tract fistula — n=213, PRR 14.3
- Chronic kidney disease-mineral and bone disorder — n=132, PRR 14.2
- Radiculopathy — n=289, PRR 12.5
- Respiratory arrest — n=2,808, PRR 11.4
- Nephrogenic anaemia — n=450, PRR 10.8
- Hyperparathyroidism secondary — n=242, PRR 10.7
✓ A hand-written Bradford Hill causality assessment exists for this drug: Alprazolam (benzodiazepines) ↔ Drug dependence / abuse.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Alprazolam?
In FDA FAERS, the most frequently co-reported reaction terms for Alprazolam are nausea, fatigue, anxiety, headache, pain, toxicity to various agents. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Alprazolam have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate.
Do FAERS signals prove that Alprazolam causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 0dce8232-0b0e-4f81-af95-36e6febdb550, effective 20260519; matched on
openfda.generic_name.exact:"ALPRAZOLAM" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - PubChem CID 2118 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,153 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
ALPRAZOLAM, results-bearing studies sorted by enrollment)
Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.